OrthoLogic changes indication for spinal fusion product
This article was originally published in Clinica
OrthoLogic has submitted an amended premarket approval supplement for its SpinaLogic-1000 spinal fusion devices to the US FDA. The changes were made in response to questions put forward by the FDA at a meeting in mid December last year.
You may also be interested in...
The WHO’s new "living guideline" against remdesivir’s use in hospitalized patients notwithstanding, some key opinion leaders in India see a role for the antiviral, but underscore that COVID-19 is still in its infancy and all repurposed therapies for the disease still have a long way to go. They also see the US remdesivir studies as more robust.
Join us for a brief audio tour around the past week's major global biopharma industry developments, in this podcast version of Scrip's Five Must-Know Things.
A recent Department of Health and Human Services proposal to review regulations every 10 years may mean good things for the device industry, said David Hoffmeister, partner, Wilson Sonsini Goodrich & Rosati.